Rectally absorbable form of L-dopa |
| What is claimed is: 1. A method of enhancing the rate of absorption of a rectally administered ... |
|
Rectally absorbable form of L-dopa |
| What is claimed is: 1. A method of enhancing the rate of absorption of a rectally administered ... |
|
Rectally absorbable form of L-dopa |
| What is claimed is: 1. A pharmaceutical composition for enhancing rectal absorption of L-dopa by ... |
|
Method to treat Parkinsons disease |
| I claim: 1. The method of treatment of Parkinson's disease and related neurological syndromes which ... |
|
Method of using cytoprotective alcohols to treat neural disease and neural injury |
| The present invention is grounded in the surprising discovery that hexacosanol and analogues and ... |
|
Methods of treating Parkinson's disease using melanin |
| OF THE INVENTION One aspect of the present invention relates to the treatment of a mammal having a ... |
|
Method of treating memory disorders using R-enantiomers of N-propargyl-aminoindan compounds |
| OF THE INVENTION The present invention thus provides as a novel compound the R(+)-enantiomer of N-... |
|
L-DOPA ethyl ester to treat Parkinson's disease |
| OF THE INVENTION This invention provides a composition which comprises a pharmaceutically ... |
|
Episomal vector systems and related methods |
| The present invention provides papilloma virus episomal vector systems and methods for papilloma ... |
|
Method for treating Parkinson's disease employing an ATP-sensitive potassium channel blocker |
| What is claimed is: 1. A method for treating Parkinson's disease, which comprises administering ... |
|
|
Non-antigenic branched polymer conjugates
| Details |
Inventors: Greenwald, Richard B.; Martinez, Anthony J.;
Assignee: Enzon, Inc. (Piscataway, NJ)
Primary Examiner: Gulakowski; Randy
Assistant Examiner:
Attorney, Agent or Firm: Roberts & Mercanti LLP
Branched, substantially non-antigenic polymers are disclosed. Conjugates prepared with the polymers and biologically active molecules such as proteins and peptides demonstrate extended circulating life in vivo. Substantially fewer sites on the biologically active material are used as attachment sites. Methods of forming the polymer, conjugating the polymers with biologically active moieties and methods of using the conjugates are also disclosed. |
|
DETAILED DESCRIPTION OF THE INVENTION 1. POLYMER SUBSTITUENTS AND FORMULA (I) DEFINED The activated branched polymers of the present invention are preferably prepared from poly(alkylene oxides) (PAO's) that are water soluble at room temperatures. Within this group are alpha-substituted polyalkylene oxide derivatives such as methoxypoly (ethylene glycols) (mPEG) or other suitable alkyl substituted PAO derivatives such as those containing mono or bis terminal C. sub. 1 -C. sub. 4 groups. Straight-chained non-antigenic polymers such as monomethyl PEG homopolymers including ##STR2## and mPEG--O--CH. sub. 2 --CH. sub. 2 -- are preferred. Alternative polyalkylene oxides such as other poly(ethylene glycol) homopolymers, other alkyl-poly(ethylene oxide) block copolymers, and copolymers of block copolymers of poly(alkylene oxides) are also useful. The polymers of the present invention are represented by Formula (I): (R). sub. n L--A (I) wherein: (R) includes a water-soluble, substantially non-antigenic polymer; (n)=2 or 3; (L) is an aliphatic linking moiety covalently linked to each (R); and (A) represents an activating functional group capable of undergoing nucleophilic substitution. Each (R) can be a water-soluble, substantially non-antigenic polymer chain. When the polymer chains are PEG or mPEG, it is preferred that each chain have a molecular weight of between about 200 and about 80,000 daltons and preferably between about 2,000 and about 42,000 daltons. Molecular weights of about 5,000 to about 20,000 daltons are most preferred. Alternative polymeric substances include materials such as dextrans, polyvinyl pyrrolidones, polyacrylamides or other similar non-immunogenic polymers. Such polymers are also capable of being functionalized or activated for inclusion in the invention. The foregoing is merely illustrative and not intended to restrict the type of non-antigenic polymers suitable for use herein. In another embodiment of the invention, (R) is a branched polymer for secondary and tertiary branching from a bioactive material
|
| Related patents |
|
|
Substantially pure histidine-linked protein polymer conjugates
In one aspect, the present invention includes substantially pure protein-polymer conjugates. The conjugates include a protein, such as an alpha interferon, covalently ...
|
|
|
Crosslinked polymer compositions and methods for their use
The present invention discloses a crosslinked polymer composition comprising a first synthetic polymer containing two or more nucleophilic groups, and a second synthetic ...
|
|
|
Conjugation of polypeptides
OF THE INVENTION It is the object of the invention to provide polypeptide conjugates with reduced allergenicity. As described above it is well-known according to prior ...
|
|
|
High molecular weight polymer-based prodrugs
OF THE INVENTION A. THE PRODRUGS In most aspects of the invention, the prodrug compositions of the present invention contain hydrolyzable linkages between the polymer ...
|
|
|
Non-antigenic amine derived polymers and polymer conjugates
In one aspect of the invention, there are provided amine-based polymer intermediates having the formula: R--B (I) wherein (R) is a water-soluble, substantially non-...
|
|
|
Biodegradable high molecular weight polymeric linkers and their conjugates
The present invention includes compounds of the formula: (D).sub.n --M--(R.sub.1).sub.m (I) wherein (m) and (n) independently selected positive integers, preferably from ...
|
|
|
Modified polypeptides with high activity and reduced allergenicity
OF THE INVENTION The modified polypeptide of the present invention is represented by the formula: A-B.sub.n containing, as essential components, a enzyme, A, and a ...
|
|
|
Poly(ethylene glycol) derivatives with proximal reactive groups
OF THE INVENTION The terms "group," "functional group," "moiety," "active moiety," "reactive site," reactive group" and "reactive moiety" are used in the art and herein ...
|
|
|
Devices for cloaking transplanted cells
A variety of devices can be used to contain or cloak a source of a therapeutic substance, often cells, which source provides the substance to a host or recipient subject....
|
|
|
Terminally-branched polymeric linkers and polymeric conjugates containing the same
In one aspect of the invention, compounds of Formula (I) are provided: ##STR6## wherein: J is ##STR7## E.sub.1-4 are independently selected from the group consisting of ...
|
|
|